Mon. 17 Jun 2024, 3:32am ET
Benzinga
News
- Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations
- Clinical responses in CLL patients were rapid and deepening with longer time on treatment
- Nurix intends to advance NX-5948 into pivotal trial(s) in 2025